B
Bullisch
Bullisch · 25%COO
$100.88
Szenariopreis
$54.880
+0.291 (+0.53%)Zum Schluss
Loading chart…
- Hoch
- 55.240
- Eröffnung
- 54.590
- Volumengewichteter Durchschnittskurs
- 54.68
- Volumen
- 3.41M
- Marktkap.
- 17.45B
- Tief
- 53.920
- Umsatz
- 186.59M
- EV/EBITDA, TTM
- 9.95
The Cooper Companies, Inc. is a medical device company. The Company's segments include CooperVision and CooperSurgical. The CooperVision segment is engaged in developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics. Its daily disposable silicone hydrogel contact lens products include MyDay daily disposable, MyDay daily disposable toric, MyDay daily disposable multifocal, and MyDay Energys. The CooperSurgical segment provides a portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. Its brands include ALLY II UPS, Advincula Delineator, Apple-Hunt Secondary Cannula, Bakri Postpartum Balloon, California Cryobank, Carter-Thomason, Cell Care, Cells for Life, Coda, Cord Blood Registry, Core Cryolab, Donor Egg Bank USA, ER-Complete, Embryo Options, and Endosee.
KI-Analyse of Cooper Companies Inc (COO)
HaltenCurrently, Cooper Companies Inc is trading at $54.37, which is below the average analyst price target of $73. This suggests potential upside. However, the RSI is at 27.192, indicating the stock is oversold, which could lead to a price rebound. The company has shown a significant net income increase to $432.8 million in Q3 2026, but it also reported a net loss of $77.9 million in Q2 2026, indicating volatility. The main risk is the forecasted revenue growth of only 0% to 2% for Q4 2026, which could limit short-term price appreciation.
Analystenbewertungen (15)
+64.60% Aufwärtspotenzial
Kaufen
10 Kaufen
5 Halten
0 Verkaufen
Aktuell: 54.88
Tief
73.00
Durchschnitt
90.33
Hoch
100.00
Barclays
Equal Weight
$60
2026-10-06
Barclays
2026-10-06
Kursziel
$60
Equal Weight
Mizuho
Überdurchschnittlich
$75
2026-09-11
Mizuho
2026-09-11
Kursziel
$75
Überdurchschnittlich
JPMorgan
Neutral
$58
2026-09-10
JPMorgan
2026-09-10
Kursziel
$58
Neutral
Needham
Kaufen
$73
2026-09-10
Needham
2026-09-10
Kursziel
$73
Kaufen
Citi
Neutral
$60
2026-09-10
Citi
2026-09-10
Kursziel
$60
Neutral
Bewertungskennzahlen
Das aktuelle erwartete KGV von Cooper Companies Inc (COO) beträgt 11.34, verglichen mit dem 5-Jahres-Durchschnitt von 22.87.
Alphio-AI-Kursszenarien für COO
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die COO halten
Event-Zeitleiste
News
7.010-13PRnewswireRosen Law Firm Investigates Securities Claims Against The Cooper Companies
5.010-07FoolKurzius Increases Stake in Cooper Companies
5.010-07FoolDirector Paul A. Keel Acquires $250,000 in Cooper Companies Shares
5.010-06FoolCooper Companies Director Increases Stock Holdings
7.010-05PRnewswireRosen Law Firm Investigates Securities Claims Against Cooper Companies
COO FAQ – beantwortet von Alphio AI
The Cooper Companies, Inc. is a medical device company. The Company's segments include CooperVision and CooperSurgical. The CooperVision segment is engaged in developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics. Its daily disposable silicone hydrogel contact lens products include MyDay daily disposable, MyDay daily disposable toric, MyDay daily disposable multifocal, and MyDay Energys. The CooperSurgical segment provides a portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. Its brands include ALLY II UPS, Advincula Delineator, Apple-Hunt Secondary Cannula, Bakri Postpartum Balloon, California Cryobank, Carter-Thomason, Cell Care, Cells for Life, Coda, Cord Blood Registry, Core Cryolab, Donor Egg Bank USA, ER-Complete, Embryo Options, and Endosee. It operates in the Healthcare sector (OPHTHALMIC GOODS industry).
Currently, Cooper Companies Inc is trading at $54.37, which is below the average analyst price target of $73. This suggests potential upside. However, the RSI is at 27.192, indicating the stock is oversold, which could lead to a price rebound. The company has shown a significant net income increase to $432.8 million in Q3 2026, but it also reported a net loss of $77.9 million in Q2 2026, indicating volatility. The main risk is the forecasted revenue growth of only 0% to 2% for Q4 2026, which could limit short-term price appreciation.
15 analysts cover COO: 10 rate it Buy, 5 Hold and 0 Sell. The average price target is 90.33.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.